Fragment-based activity space: smaller is better.

Area of Science:

• Medicinal Chemistry
• Structural Biology
• Drug Discovery

Background:

• Traditional high throughput screening (HTS) faces limitations in chemical diversity and binding efficiency for certain molecular targets.
• Fragment-based drug discovery (FBDD) presents a promising alternative, leveraging smaller, more efficient binders.
• Structure determination is crucial for identifying suitable molecular targets for FBDD.

Purpose of the Study:

• To advocate for fragment-based drug discovery as a superior method over traditional high throughput screening.
• To highlight the advantages of fragment collections in achieving better chemical diversity coverage.
• To propose an optimized workflow for fragment screening and hit validation.

Main Methods:

• Utilizing fragment collections for broader chemical diversity compared to larger HTS libraries.
• Employing high-concentration bioassays for sensitive fragment screening.
• Confirming fragment hits using Nuclear Magnetic Resonance (NMR) spectroscopy.
• Determining the structure of confirmed fragment-ligand complexes via X-ray crystallography.

Main Results:

• Fragment collections provide better chemical diversity coverage with a smaller compound set.
• Fragments demonstrate a higher probability of being efficient target binders.
• High-concentration bioassays coupled with NMR offer effective hit identification and confirmation.
• X-ray crystallography enables detailed structural analysis of fragment-protein interactions.

Conclusions:

• Fragment-based drug discovery is a powerful strategy that can potentially replace traditional HTS for specific targets.
• The proposed methodology combining high-concentration bioassays, NMR, and X-ray crystallography enhances the efficiency of FBDD.
• FBDD facilitates the discovery of potent and structurally characterized drug leads.